Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study

Menni, Cristina; Valdes, Ana M.; Polidori, Lorenzo; Antonelli, Michela; Penamakuri, Satya; Nogal, Ana; Louca, Panayiotis; May, Anna; Figueiredo, Jane C.; Hu, Christina; Molteni, Erika; Canas, Liane S; Österdahl, Marc F.; Modat, Marc; Sudre, Carole H.; Fox, Ben; Hammers, Alexander; Wolf, Jonathan; Capdevila, Joan; Chan, Andrew T.; David, Sean P.; Steves, Claire J.; Ourselin, Sébastien; Spector, Tim D.

doi:10.1016/s0140-6736(22)00327-0

Cited by 732 publications

(816 citation statements)

References 23 publications

Supporting

Mentioning

698

Contrasting

Unclassified

Order By: Relevance

“…We found that 84.9%, 56.6%, and 28.3% of patients with Omicron had fever, sore throat, and runny nose, respectively, but none of which lasted more than 2 months within 3 months since the onset of the disease. Cristina Menni et al reported that sore throat was more common with Omicron than with Delta variant (70.5% vs 60.8%, odds ratio 1.55; 95% CI 1.43–1.69, p<0.001) [7], indicating that patients with Omicron tended to have upper respiratory symptoms. This is also consistent with an in vitro study stating that Omicron replicates faster than all other SARS-CoV-2 variants in the bronchus but less efficiently in the lung parenchyma, and appears to enter human cells by a different route [22].…”

Section: Discussionmentioning

confidence: 99%

“…This is also consistent with an in vitro study stating that Omicron replicates faster than all other SARS-CoV-2 variants in the bronchus but less efficiently in the lung parenchyma, and appears to enter human cells by a different route [22]. Although we could not compare the prevalence and duration of these symptoms of Omicron with those of previous strains, characterizing the clinical course of infection by Omicron is not only of direct public health relevance providing public and clinicians awareness on what symptoms to look out for, but will also assist in understanding the potential effects of future variants of concern [7].…”

Section: Discussionmentioning

confidence: 99%

“…A prospective longitudinal observational study revealed the difference in the prevalence of acute-phase symptoms in patients with Omicron and Delta variants of SARS-CoV-2 [7]. In particular, sore throat was more common in Omicron than in Delta, while loss of smell was infrequent in Omicron than Delta.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Post COVID-19 condition of the Omicron variant of SARS-CoV-2

Morioka

Tsuzuki

Suzuki

et al. 2022

Preprint

View full text Add to dashboard Cite

BackgroundNo epidemiological data on post coronavirus disease (COVID-19) condition due to Omicron variant has been reported yet.MethodsThis was as a single-center, cross-sectional study, that interviewed via telephone the patients who recovered from Omicron COVID-19 infection (Omicron group), and surveyed via self-reporting questionnaire those patients infected with other strains (control group). Data on patients’ characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted at least 2 months within 3 months since the onset of COVID-19. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching.ResultsWe conducted interviews for 53 out of 128 patients with Omicron, and obtained 502 responses in the control group. After matching, 18 patients each in Omicron and control group had improved covariate balance of the older adult, female sex, obese patients, and vaccination status. There were no significant differences in the prevalence of each post-acute COVID-19 symptoms between the two groups. The numbers of patients with at least one post-acute COVID-19 symptom in the Omicron and the control group were 1 (5.6%) and 10 (55.6%) (p=0.003), respectively.ConclusionThe prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with more participants is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Post COVID-19 condition of the Omicron variant of SARS-CoV-2

Morioka

Tsuzuki

Suzuki

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Hospitalized patients infected with the Delta variant showed severer symptoms and longer periods of illness (Ong et al, 2021; Twohig et al, 2021). In comparison, Omicron infections is associated with a 70% smaller chances of severe cases (Wolter et al, 2022) and shorter period of illness (Menni et al, 2022) than that of the Delta variant. These phenomena, along with the mutations accumulated in the Delta variant, have validated the descending effectiveness of the current vaccines (Lopez Bernal et al, 2021; McCallum et al, 2021b; Wall et al, 2021) and drugs (Mlcochova et al, 2021).…”

Section: Introductionmentioning

confidence: 95%

In situ architecture and membrane fusion of SARS-CoV-2 Delta variant

Song

Yao

et al. 2022

Preprint

View full text Add to dashboard Cite

SUMMARYAmong the current five Variants of Concern, infections caused by the SARS-CoV-2 B.1.617.2 (Delta) variant are often associated with the greatest severity. Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, architecture of intact Delta virions remains veiled. Moreover, the detailed mechanism of S-mediated membrane fusion remains elusive. Here we report the molecular assembly and fusion snapshots of the authentic Delta variant. Envelope invagination and fusion events were frequently observed. Native structures of pre- and postfusion S were determined up to 4.1-Å resolution. Site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S over that of the Wuhan-Hu-1 S. Based on these findings, we proposed a model for S-mediated membrane fusion and a model for the invagination formation.In BriefCryo-ET of intact SARS-CoV-2 Delta variant revealed its unique architecture and captured snapshots of its membrane fusion in action.

show abstract

“…Clinical trials have demonstrated that a third heterologous booster vaccination by EUA SARS-CoV-2 mRNA vaccines (BNT162b2 and mRNA-1273) increased neutralizing antibody titer accompanied by better prevention and lower disease severity than the initial two doses with BBIP-CorV or CoronaVac during the Gamma and Delta epidemics (Accorsi et al, 2022; Cerqueira-Silva et al, 2022; Costa Clemens et al, 2022; Moghnieh et al, 2021; Zeng et al, 2021). After the emergence of the Omicron variants, some cohort studies reported that Omicron BA.1 infection was associated with milder disease and shorter duration of clinical symptoms than Delta infection (Davies et al, 2022; Houhamdi et al, 2022; Jassat et al, 2022; Kim et al, 2022; Maslo et al, 2022; Menni et al, 2022; Wolter et al, 2022). The third vaccination was helpful in reducing the infection and hospitalization rates during the Delta and Omicron BA.1 prevalence in other countries (Accorsi et al, 2022; Thompson et al, 2022; Yoon et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2

Zhou

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

SummaryThe ongoing outbreak of SARS-CoV-2 Omicron BA.2 infections in Hong Kong, the world model city of universal masking, has resulted in a major public health crisis. In this study, we investigate public servants who had been vaccinated with two dose (82.7%) or three dose (14%) of either CoronaVac (CorV) or BNT162b2 (BNT). During the BA.2 outbreak, 29.3% vaccinees were infected. Three-dose vaccination provided protection with lower incidence rates of breakthrough infections (2×BNT 49.2% vs 3×BNT 16.6%, p<0.0001; 2×CorV 48.6% vs 3×CoV 20.6%, p=0.003). The third heterologous vaccination showed the lowest incidence (2×CorV+1×BNT 6.3%). Although BA.2 conferred the highest neutralization resistance compared with variants of concern tested, the third dose vaccination-activated spike-specific memory B and Omicron cross-reactive T cell responses contributed to reduced frequencies of breakthrough infection and disease severity. Our results have implications to timely boost vaccination and immune responses likely required for vaccine-mediated protection against Omicron BA.2 pandemic.

show abstract

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study

Cited by 732 publications

References 23 publications

Post COVID-19 condition of the Omicron variant of SARS-CoV-2

Post COVID-19 condition of the Omicron variant of SARS-CoV-2

In situ architecture and membrane fusion of SARS-CoV-2 Delta variant

Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2

Contact Info

Product

Resources

About